Skip to main content

Combined versus single locoregional therapy
in the treatment of unresectable hepatocellular
carcinoma

Research Authors
Moustafa H.M. Othman a, Amr F. Mourad b, Mohamed M.H. Abd Ellah b,*,
Hala M.K. Imam c
Research Journal
The Egyptian Journal of Radiology and Nuclear Medicine
Research Publisher
Elsevier B.V.
Research Rank
2
Research Vol
45
Research Website
http://www.sciencedirect.com/science/article/pii/S0378603X14000461
Research Year
2014
Research_Pages
395–401
Research Abstract

Abstract Introduction: Surgical and locoregional therapies are different options in HCC treatment,
several locoregional techniques are used.
Purpose: This study aimed to assess the effectiveness of transarterial chemoembolization (TACE),
radiofrequency ablation (RFA) and combined therapy, in HCC management.
Materials and methods: The study was conducted at our University Hospital, from August 2011 to
February 2013. It included 60 patients with HCC (40 males and 20 females, age ranged between 45
and 70 years). Patients were classified into 3 groups, group 1 treated with TACE, group 2 with
RFA, and group 3 with both techniques. Response was assessed by triphasic CT and alpha fetoprotein.
Patients were classified into good and poor responders after one and six months and one year.
Patients’ survival and incidence of recurrence were recorded.
Results: The percentage of good responders was greater with combined therapy than with TACE and
RFA (90%, 70%, and 60% respectively). The overall survival was 75%and the recurrence free survival
was 60% in TACE, 90%, and 45% in RFA and 95% and 90% in combined therapy respectively.
Conclusion: Combined therapy is superior regarding good response, overall survival, and free recurrence
survival than either TACE or RFA alone.